Primary vs. Secondary Hypogonadism: How to Tell Which Type You Have (And Why It Changes Everything)

Executive Summary

When a doctor tells you your testosterone is low, the conversation usually jumps quickly to treatment options: TRT, supplements, lifestyle changes. What almost never gets discussed is the question that should come first: why is your testosterone low? The answer determines whether your condition is permanent or reversible, whether TRT is your best option or a premature choice, whether enclomiphene can work for you, and whether lifestyle optimization will actually move the needle. Without that answer, treatment decisions are essentially guesses.

The two main categories — primary hypogonadism (the problem is in the testes) and secondary hypogonadism (the problem is upstream, in the hypothalamus or pituitary) — are distinguished by a single pair of lab values most men never get: LH and FSH. These two hormones are the pituitary's signals telling the testes to produce testosterone. Whether they are elevated, normal, or suppressed is the critical diagnostic fork in the road. High LH/FSH means the brain is shouting and the testes are not responding — that is primary hypogonadism. Low or low-normal LH/FSH means the brain is not sending the signal in the first place — that is secondary hypogonadism, and it is often caused by something correctable.

This guide explains the full diagnostic picture, what each type means for treatment, and how to make sure you are making an informed decision before committing to a lifelong hormone protocol. For the full lab interpretation context, see how to read testosterone lab results. If you are still deciding whether TRT is even necessary, start with TRT vs. natural testosterone boosting.

At-a-Glance Comparison

Distinguishing primary from secondary hypogonadism based on lab pattern, cause, and treatment implications. LH and FSH are the essential diagnostic markers; they must be included in any complete hypogonadism workup. Updated March 2026.

Why LH and FSH Are the Most Important Labs You Probably Never Got

Total testosterone tells you that there is a problem. LH and FSH tell you where the problem is. Most standard testosterone test panels — including the ones offered by many direct-to-consumer labs and basic clinic workups — omit LH and FSH entirely. This means a significant percentage of men receiving a low testosterone diagnosis have never actually received a diagnosis at all: they have received a lab result without the additional data required to interpret it clinically. A total testosterone of 275 ng/dL with elevated LH and a total testosterone of 275 ng/dL with suppressed LH are two different medical situations with different causes, different treatment logic, and different long-term trajectories. Treating both identically is a clinical error — and it happens routinely. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

LH (luteinizing hormone) is released by the pituitary in pulses and travels through the bloodstream to the Leydig cells in the testes, where it stimulates testosterone production. FSH (follicle-stimulating hormone) from the same pituitary pulse drives spermatogenesis in the Sertoli cells. The two-hormone pattern is the body's primary diagnostic signal for the location of hypogonadism. Elevated LH + Elevated FSH with Low Testosterone: The pituitary is working correctly — it is sending maximum signal. The testes are not responding. This is primary hypogonadism (also called hypergonadotropic hypogonadism). The failure is at the gonadal level. Common causes include Klinefelter syndrome (XXY chromosomal pattern), testicular injury from trauma or surgery, history of undescended testes (cryptorchidism), radiation or chemotherapy effects on the testes, viral orchitis (mumps orchitis being the classic case), and age-related gonadal decline in older men. Low or Low-Normal LH + Low or Low-Normal FSH with Low Testosterone: The testes would respond to appropriate stimulation, but the hypothalamic-pituitary signal is suppressed or absent. This is secondary hypogonadism (also called hypogonadotropic hypogonadism). The pituitary is not driving the axis. This pattern has a much longer list of reversible causes — obesity, sleep apnea, anabolic steroid history, opioid use, hyperprolactinemia (elevated prolactin from a pituitary adenoma), hypothyroidism, and idiopathic causes. It is also the mechanism by which exogenous testosterone (TRT) suppresses natural production: when you take exogenous T, the brain detects adequate circulating testosterone and stops signaling the pituitary, which stops driving the testes — an iatrogenic secondary hypogonadism. See how to read testosterone lab results for the full lab panel interpretation guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men who receive a low testosterone result without LH and FSH are effectively making treatment decisions without the most important piece of diagnostic information. A direct-to-consumer testosterone kit that shows 'low' without LH/FSH is not a diagnosis — it is a starting point for a diagnosis. Requesting the additional labs is a one-step intervention that fundamentally changes the treatment pathway. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Primary Hypogonadism: What It Means, Common Causes, and Why TRT Is Usually the Right Call

Primary hypogonadism is a structural failure of the gonads themselves. The hypothalamus and pituitary are functioning correctly — LH and FSH are elevated because they are trying to stimulate a response that the testes cannot provide. No amount of lifestyle optimization, supplementation, or upstream signaling intervention will fix a testicular problem. This is the category where TRT is not just an option — it is typically the only clinically viable path to normal testosterone levels. The important implications: men with primary hypogonadism should not spend months in a lifestyle optimization window expecting natural T recovery; the biological mechanism for that recovery is absent. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The most common causes of primary hypogonadism in clinical practice are: Klinefelter Syndrome (XXY) — the most common genetic cause, occurring in approximately 1 in 500–600 males. Many men with Klinefelter are undiagnosed because the presentation is variable: some have severe hypogonadism diagnosed in adolescence, others have subclinical cases only identified through fertility evaluation or hormone panels in adulthood. Classic features include small testes, reduced body hair, gynecomastia tendency, and infertility. Testosterone is almost always low and TRT is standard of care. Orchitis — inflammation of the testes from infection, most commonly mumps orchitis in unvaccinated men, which can permanently damage Leydig cell function in the affected testis or testes. STI-related orchitis from gonorrhea or chlamydia can also cause permanent gonadal damage. Testicular trauma or torsion — physical injury sufficient to damage testicular tissue, or testicular torsion that resulted in reduced blood supply and gonadal damage. Undescended testes (cryptorchidism) — testes that did not fully descend by age 1 and were not surgically corrected early have higher rates of subsequent gonadal dysfunction and low T. Chemotherapy and radiation — alkylating agents (cyclophosphamide, cisplatin) and radiation to the pelvic/gonadal region cause permanent or partial Leydig cell damage in a dose-dependent fashion. Many cancer survivors have primary hypogonadism as a treatment consequence. Age-related gonadal decline — Leydig cell function naturally decreases with age; in some older men this produces a true primary hypogonadism pattern (elevated LH + low T) rather than the mixed-pattern late-onset hypogonadism more commonly observed. For men with confirmed primary hypogonadism, the treatment path is TRT with good monitoring. Use compare TRT providers to evaluate options, and review TRT side effects and TRT cost before deciding on a provider. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Fertility implications in primary hypogonadism are significant and often permanent. Men with Klinefelter syndrome and other primary causes often have severely impaired or absent spermatogenesis regardless of TRT status. Fertility counseling from a reproductive endocrinologist should be part of the workup for men of reproductive age with confirmed primary hypogonadism who want biological children. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Secondary Hypogonadism: Reversible Causes, What to Check, and When to Treat

Secondary hypogonadism is the category where the diagnostic work matters most — because many of its causes are reversible, and treating the cause rather than just the symptom (low T) is often the better long-term outcome. In secondary hypogonadism, the testes are capable of producing testosterone but the pituitary is not driving them to do so. If you can identify and address the reason the pituitary signal is suppressed, testosterone levels may recover to normal without any exogenous hormone intervention. This is not guaranteed — many men with secondary hypogonadism have idiopathic or irreversible causes — but the triage is worth doing before committing to a lifelong protocol. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The most common reversible causes of secondary hypogonadism: Obesity and metabolic syndrome: Adipose tissue — especially visceral fat — aromatizes testosterone to estradiol and suppresses GnRH pulsatility at the hypothalamus. The HPG axis suppression from obesity is dose-dependent: the more excess body fat, especially visceral, the more profound the suppression. A 10–15% reduction in body weight in obese men with secondary hypogonadism can raise testosterone by 100–200 ng/dL through this mechanism alone, often without any other intervention. This is the strongest evidence base for lifestyle optimization in secondary hypogonadism. Obstructive sleep apnea: Testosterone is predominantly produced during sleep, particularly during REM phases. Obstructive sleep apnea disrupts REM cycles, fragments testosterone production pulses, and produces chronic intermittent hypoxia that impairs Leydig cell function. Undiagnosed and untreated sleep apnea is a surprisingly common driver of secondary hypogonadism, particularly in overweight men. CPAP treatment for OSA raises testosterone meaningfully in men where OSA is the primary suppressor. Prior anabolic steroid use: Exogenous androgens from anabolic steroid cycles suppress pituitary LH and FSH release (the same mechanism as TRT). In some men, HPG axis suppression persists long after steroid discontinuation — lasting months to years. This is called post-cycle hypogonadism or hypogonadism after anabolic steroid use, and it falls in the secondary category because the pituitary-axis signal is suppressed, not the testes themselves. Recovery is possible with SERMs (clomiphene, enclomiphene) or time, but some men have persistent suppression. Opioid-induced androgen deficiency (OPIAD): Chronic opioid use suppresses hypothalamic GnRH release and reduces pituitary LH/FSH pulsatility, producing secondary hypogonadism in a significant proportion of long-term users. This is dose-dependent and present across opioid types including methadone, buprenorphine, and prescription opioids. For men on long-term opioid therapy with low T, this is a likely cause — and if opioid dose can be reduced (in coordination with the prescribing physician), testosterone levels often improve. Hyperprolactinemia: Elevated prolactin — from a pituitary adenoma (prolactinoma), medication side effects (antipsychotics, metoclopramide, SSRIs at high doses), or other causes — suppresses hypothalamic GnRH release and reduces LH/FSH output. Prolactinoma is a benign pituitary tumor and one of the more commonly missed endocrine causes of secondary hypogonadism. Prolactin should be included in any comprehensive hypogonadism workup. Treatment of the prolactinoma (dopamine agonists like cabergoline) often restores testosterone levels without TRT. Hypothyroidism: Thyroid hormone deficiency affects multiple steps in the testosterone synthesis and metabolism pathway. Hypothyroidism can produce low T via several mechanisms including SHBG changes and direct Leydig cell effects. Correcting hypothyroidism often improves testosterone levels in men where it is the primary driver. Chronic illness and caloric restriction: Severe chronic illness, significant caloric deficit, and overtraining syndrome can all suppress the hypothalamic-pituitary axis via cortisol-driven and GnRH-suppressive mechanisms. Long-distance endurance athletes in caloric deficit are an example of a population at risk for functional secondary hypogonadism. Read TRT vs. natural testosterone boosting for the evidence-based decision framework on when to try lifestyle optimization vs. when to proceed directly to medical treatment. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The investigation of secondary hypogonadism causes is itself a clinical gate. A provider who diagnoses low T from a testosterone-only panel and immediately offers TRT without addressing LH/FSH and reversible causes is skipping the most important diagnostic step. Men who start TRT before investigating reversible secondary causes may be committing to a lifelong protocol that would not have been necessary if the underlying suppressor had been identified and addressed. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Enclomiphene and SERMs: Why They Only Work for Secondary Hypogonadism

The growing popularity of enclomiphene (and older clomiphene citrate) as a TRT alternative has created significant consumer confusion about when it is an appropriate treatment. The answer is mechanistically straightforward: enclomiphene stimulates the body's own testosterone production by blocking estradiol's negative feedback at the hypothalamus, which increases GnRH pulsatility, which increases LH and FSH release, which drives the testes to produce more testosterone. For this mechanism to produce a therapeutic effect, the testes must be capable of responding to elevated LH and FSH stimulation. In secondary hypogonadism, the testes are capable — they are just not being driven. In primary hypogonadism, the testes are not capable of responding regardless of how high LH goes. Enclomiphene is clinically appropriate only for secondary hypogonadism. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

This mechanism explains the otherwise confusing market situation where Hims prescribes enclomiphene but bills it as a testosterone-optimization treatment: Hims is prescribing an appropriate treatment, but for a specific patient profile (secondary hypogonadism, intact testicular function) that not every man searching 'Hims TRT' has been screened for. The detail that Hims prescribes enclomiphene rather than exogenous testosterone is covered in full in Hims vs. Roman vs. Maximus TRT comparison. The relevant point here is the diagnostic gate: enclomiphene is only appropriate if LH and FSH are low or low-normal, confirming that the HPG axis is the underperforming component, not the testes. The expected clinical response to enclomiphene in secondary hypogonadism is a rise in LH and FSH within 2–4 weeks, followed by a rise in total testosterone over 4–12 weeks. Studies using enclomiphene in men with secondary hypogonadism report average testosterone increases to 400–600 ng/dL, with responders maintaining fertility — spermatogenesis is preserved because the testes remain active under LH/FSH stimulation, unlike exogenous TRT which suppresses it. The key advantage over TRT: enclomiphene preserves the HPT axis. Men can discontinue it (under medical supervision) with a recovery of natural testosterone production, something that is more complicated after years of exogenous testosterone suppression. The disadvantages: enclomiphene raises estradiol (because higher LH produces more testosterone, which aromatizes to estradiol), some men experience mood changes from SERM activity on brain estrogen receptors, and it does not produce testosterone levels as high or as predictably as exogenous TRT in most protocols. For men with secondary hypogonadism who are fertility-conscious or who want to preserve natural HPT function, enclomiphene is a legitimate and often overlooked option. See best online enclomiphene clinics in 2026 for provider options. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men presenting to telehealth platforms with primary hypogonadism who are prescribed enclomiphene are receiving a treatment that cannot work for their condition — and are delaying appropriate treatment (TRT) while paying for an ineffective protocol. This is the most important clinical failure mode of the enclomiphene prescription model at consumer telehealth scale. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Full Diagnostic Workup: What to Ask For and How to Interpret Results

A complete hypogonadism workup is not a single testosterone test. It is a coordinated panel that identifies the level of dysfunction (primary vs. secondary), rules out reversible causes, establishes baseline values for monitoring, and rules in or out conditions that can mimic low-T symptoms without being caused by it. Many men — particularly those accessing testosterone through consumer telehealth platforms — have never received a complete workup. Understanding what 'complete' looks like is the first step toward ensuring you are getting an accurate diagnosis. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Minimum complete diagnostic panel for new hypogonadism workup: Total Testosterone: Morning draw (7–10am), two separate occasions if borderline (300–400 ng/dL), to account for day-to-day variation. Free Testosterone or SHBG: Calculated or equilibrium dialysis free T, or SHBG for calculation. Total T can be misleadingly normal when SHBG is high (binding more T and leaving less bioavailable), making free T the functional measure. See how to read testosterone lab results for the full interpretation. LH and FSH: The essential diagnostic duo. High LH/FSH = primary. Low/normal LH/FSH = secondary. These two values are the primary/secondary discriminator and must not be omitted. Sensitive Estradiol (E2): Standard E2 assays have poor precision in the male range; sensitive or LC-MS/MS estradiol is the appropriate assay. Estradiol levels inform aromatase activity, which is elevated in obesity and affects both treatment choice and monitoring. Prolactin: Elevated prolactin is an under-recognized secondary suppressor and a flag for possible prolactinoma. Should be included in any initial workup. TSH + Free T4: Thyroid function panel. Hypothyroidism is a direct testosterone suppressor and a conditions that mimics low-T symptoms. CBC (Complete Blood Count): Hematocrit and hemoglobin baseline. Hematocrit elevation is the most common TRT side effect requiring management; baseline is essential before starting. Comprehensive Metabolic Panel: Kidney and liver function, fasting glucose, and related metabolic markers that are baseline context for TRT monitoring. PSA (for men over 40): Prostate-specific antigen baseline before starting TRT. TRT is contraindicated in known prostate cancer and requires monitoring in men with elevated PSA. Interpreting results against reference ranges: For testosterone, 'normal' is a range — roughly 300–1000 ng/dL on most assays — but optimal for symptomatic resolution is typically 500–900 ng/dL. A number in the low-normal range (350–450 ng/dL) with significant symptoms warrants a complete workup even if a basic report flags it as 'normal.' Read what is a good testosterone level for the age-specific context. After establishing the primary/secondary distinction, the treatment decision follows a logical path. If primary: TRT is the indicated treatment. If secondary: investigate reversible causes first, then weigh TRT vs. enclomiphene vs. cause-directed treatment based on cause, fertility goals, and preference. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Lab interpretation errors — particularly treating the normal range boundary as a clinical threshold without clinical context — are a common driver of both over-treatment (TRT prescribed for 400 ng/dL without symptoms) and under-treatment (TRT not offered for 280 ng/dL because it is 'just borderline'). The lab values are inputs to a clinical judgment, not the judgment itself. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Treatment Decision Framework: Primary, Secondary Reversible, and Secondary Non-Reversible

Once you have a complete panel and understand whether you have primary or secondary hypogonadism — and if secondary, whether the cause is reversible — the treatment decision follows a structured logic. The framework has three branches, not two. Most consumer content presents TRT as the binary alternative to natural methods; the actual clinical decision space includes enclomiphene, cause-directed treatment, and watchful waiting with retesting as legitimate paths for secondary hypogonadism cases. Buyers searching for primary vs secondary hypogonadism usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The three decision branches: Branch 1 — Primary Hypogonadism: TRT is the first-line treatment. The testes cannot respond to natural or pharmacological stimulation of the HPT axis. Enclomiphene will not work. Lifestyle optimization will not produce clinically meaningful T recovery. The clinical decision is which TRT protocol and which provider. Fertility implications should be addressed before starting: sperm banking if desired, reproductive endocrinology consultation if active fertility goals. Monitoring for hematocrit elevation, estradiol, and PSA is ongoing. See best online TRT clinics in 2026 and how to get testosterone prescribed online for the next steps. Branch 2 — Secondary Hypogonadism, Reversible Cause Identified: Address the cause. Sleep apnea — CPAP trial, retest in 3–6 months. Obesity — structured weight loss program, retest at 10% body weight reduction milestone. Opioid use — discuss dose reduction with prescribing provider, retest. Hypothyroidism — thyroid hormone replacement, retest. Prolactinoma — dopamine agonist therapy (cabergoline), retest. Discontinue anabolic steroids and allow axis recovery time, optionally supported by SERMs. The treatment objective is restoration of natural HPT axis function. TRT should not be the default while a reversible cause is unaddressed. Set a defined 90–120 day timeline with specific retest milestones. If T does not recover meaningfully after genuine cause-directed intervention, proceed to pharmacological treatment. Branch 3 — Secondary Hypogonadism, Cause Not Identified or Not Reversible (Idiopathic): Pharmacological treatment is appropriate. The options are TRT or enclomiphene/clomiphene, and the choice depends on: (1) Fertility intent — enclomiphene or hCG co-administration preserves spermatogenesis; exogenous TRT suppresses it. (2) Personal preference — some men prefer preserving the natural HPT axis and are willing to accept lower and less predictable T levels than TRT delivers. (3) Symptom severity — severe hypogonadism with significantly impaired quality of life argues for TRT's more reliable and higher magnitude T elevation. (4) Previous treatment response — men who have tried enclomiphene without adequate T response or who experienced significant side effects (mood changes, gynecomastia) are better served by TRT. For side-by-side platform comparison of providers offering both TRT and enclomiphene prescribing, use compare TRT providers. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common treatment error is prescribing TRT for secondary hypogonadism with an identified, reversible cause without first attempting cause-directed treatment. Men started on TRT for obesity-driven secondary hypogonadism who subsequently lose significant weight and reverse their secondary suppression may find that their natural T production has been suppressed by exogenous testosterone, making natural recovery more complex. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Once you know whether you have primary or secondary hypogonadism — and whether your secondary cause is reversible — you are ready to evaluate provider options with the right clinical lens. Use our comparison tool to find the TRT or enclomiphene provider that fits your specific situation.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the difference between primary and secondary hypogonadism?

Primary hypogonadism means the testes themselves are not producing adequate testosterone despite receiving proper hormonal signals from the pituitary. LH and FSH are elevated because the pituitary is trying to compensate. Secondary hypogonadism means the hypothalamus or pituitary is not sending adequate stimulation to the testes — LH and FSH are low or low-normal. The testes could respond to proper stimulation but are not receiving it. The distinction is critical because it changes the treatment logic entirely.

How do I know if I have primary or secondary hypogonadism?

The distinction is made through LH and FSH blood tests. If your testosterone is low and LH/FSH are elevated, you have primary hypogonadism — the testes are failing despite maximal pituitary stimulation. If your testosterone is low and LH/FSH are low or low-normal, you have secondary hypogonadism — the pituitary is underdriving the axis. Most standard testosterone panels do not include LH and FSH; you need to request them specifically.

Can secondary hypogonadism be reversed without TRT?

Yes, in many cases — depending on the underlying cause. Obesity-driven secondary hypogonadism can improve significantly with meaningful weight loss. Sleep apnea-driven suppression often improves with CPAP treatment. Post-anabolic-steroid-use hypogonadism may recover with time or SERM support. Opioid-induced suppression may improve with dose reduction. Prolactinoma-caused secondary hypogonadism often resolves with dopamine agonist therapy. The critical first step is identifying whether a reversible cause is present before committing to TRT.

Does enclomiphene work for primary hypogonadism?

No. Enclomiphene works by stimulating LH and FSH release from the pituitary, which drives the testes to produce more testosterone. In primary hypogonadism, the testes cannot respond to elevated LH/FSH regardless of how much stimulation they receive. Prescribing enclomiphene for primary hypogonadism is mechanistically ineffective and will not produce meaningful T increases. Enclomiphene is only clinically appropriate for secondary hypogonadism with confirmed low or low-normal LH and FSH.

Why does Hims prescribe enclomiphene instead of TRT?

Hims prescribes enclomiphene because it is an effective treatment for secondary hypogonadism with intact testicular function — which is the most common pattern in the consumer male wellness market (often driven by obesity, sleep issues, or lifestyle factors). Enclomiphene stimulates natural testosterone production without suppressing the HPT axis. The critical caveat is that Hims does not prescribe exogenous testosterone (TRT), so men with primary hypogonadism or with severe secondary hypogonadism that does not respond adequately to enclomiphene will need a different provider. Full comparison at Hims vs. Roman vs. Maximus TRT comparison.

What labs do I need to diagnose primary vs. secondary hypogonadism?

Minimum required panel: total testosterone (morning draw), LH, and FSH. The LH/FSH pattern against a confirmed low testosterone is the primary/secondary discriminator. For a complete workup you also want: free testosterone or SHBG, sensitive estradiol (LC-MS/MS assay), prolactin, TSH and free T4, CBC with hematocrit, and CMP. Prolactin in particular is frequently omitted and frequently elevated in secondary hypogonadism cases where a prolactinoma is the underlying cause.

What is functional hypogonadism and how does it relate to secondary hypogonadism?

Functional hypogonadism is a subset of secondary hypogonadism where the low testosterone is driven by a specific reversible suppressor — obesity, sleep apnea, chronic illness, caloric deficit — rather than a structural or organic pituitary problem. The distinction matters because functional hypogonadism has the best prognosis for recovery without pharmacological treatment: address the cause and the HPT axis recovers. The term is used by some endocrinology guidelines to distinguish this recoverable pattern from idiopathic secondary hypogonadism where the cause is not identified.

Will TRT cause my natural testosterone production to stop permanently?

Exogenous testosterone suppresses LH and FSH release, which suppresses natural testosterone production. In most men, stopping TRT leads to gradual HPT axis recovery over weeks to months — faster with SERM support (clomiphene, enclomiphene, tamoxifen), slower without. However, recovery is not guaranteed in all cases, particularly after long-term TRT use or in men with pre-existing primary or secondary hypogonadism factors that will reassert after TRT discontinuation. Men concerned about long-term HPT axis suppression should consider enclomiphene (secondary hypogonadism) or hCG co-administration alongside TRT as options that preserve the axis.

I have high LH but normal testosterone — what does that mean?

Elevated LH with normal total testosterone can indicate early or compensated primary hypogonadism: the pituitary is increasing its drive to maintain T levels in range, but it is working harder than it should. This pattern — sometimes called 'compensated hypogonadism' — often predicts future decline as testicular reserve decreases. Free testosterone in this setting may already be reduced even if total T appears normal. If you have this pattern and symptoms, a full workup including free T and SHBG is warranted.

My testosterone is low and my doctor just offered TRT without checking LH or FSH. What should I do?

Ask specifically for LH and FSH before starting TRT. A provider who offers TRT without first checking LH and FSH is skipping the diagnostic step that determines whether TRT is your best option, whether a reversible cause should be addressed first, and whether enclomiphene is an alternative worth considering. You are not obligated to start TRT before you have a complete picture. The labs are inexpensive, widely available, and materially change the clinical logic — they are worth taking the time to get before committing to a protocol.